The issues arising from the incident with CPH2’s MFE220 electrolyser cannot now be rectified without a substantial and costly redesign and the factory acceptance testing work has been terminated. The board are pursuing alternative options that do not involve manufacturing and we think there may be value here given the IP and know-how controlled by the company. However with working capital now constrained and, with discussions with capital providers ongoing, the shares remain suspended.
